Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.58 |
| ▸ | BRD2 | P25440 | 5/20 | 0.58 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20946455 | 0.84 | BRD4 (0.57) | BRD4BRD2CREBBPFFAR1BRD3 | |
| SCHEMBL28047388 | 0.84 | BRD4 (0.57) | BRD4BRD2CREBBPFFAR1BRD3 | |
| SCHEMBL12881340 | 0.83 | BRD4 (0.59) | BRD4BRD2CREBBPFFAR1BRD3 | |
| SCHEMBL22775611 | 0.82 | BRD4 (0.60) | BRD4BRD2CREBBPFFAR1HDAC1 | |
| SCHEMBL12866840 | 0.82 | BRD4 (0.57) | BRD4BRD2CREBBPFFAR1BRD3 | |
| SCHEMBL5217255 | 0.82 | BRD4 (0.55) | BRD4BRD2CREBBPFFAR1BRD3 | |
| SCHEMBL31735473 | 0.80 | BRD4 (0.49) | BRD4BRD2CREBBP | |
| SCHEMBL3338755 | 0.80 | HTR7 (0.62) | BRD4BRD2CREBBPFFAR1 | |
| SCHEMBL3340053 | 0.80 | BRD4 (0.52) | BRD4BRD2CREBBPFFAR1BRD3 | |
| SCHEMBL22775711 | 0.78 | BRD4 (0.57) | BRD4BRD2CREBBPFFAR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855489-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-30 | — | — | US | disclosed |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, F2RL1 | BRD4 354/4885BRD2 2698/4885CREBBP 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.